63

10058-F4

63 Publications Verification

Cat. No.: HY-12702

CAS No.: 403811-55-2

Purity: 99.49%

Target:

c-Myc Autophagy

Research Areas:

Cancer

10058-F4 is a c-Myc inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

52

Ravoxertinib

52 Cited Publications

Cat. No.: HY-15947

CAS No.: 1453848-26-4

Synonyms: GDC-0994

Target:

ERK Lactate Dehydrogenase Hexokinase c-Myc

Research Areas:

Cancer

Ravoxertinib (GDC-0994) is an orally active ERK1/2 inhibitor. Ravoxertinib inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

52

Ravoxertinib hydrochloride

52 Cited Publications

Cat. No.: HY-15947A

CAS No.: 2070009-58-2

Synonyms: GDC-0994 hydrochloride

Target:

ERK Lactate Dehydrogenase Hexokinase c-Myc

Research Areas:

Cancer

Ravoxertinib hydrochloride (GDC-0994 hydrochloride) is an orally active ERK1/2 inhibitor. Ravoxertinib hydrochloride inhibits the ERK1/2 MAPK signaling pathway and reduces the expression levels of c-Myc, HK2 and LDHA. Ravoxertinib hydrochloride decreases mammosphere formation, and exerts additive and/or superadditive cytotoxicity when combined with Ipatasertib (HY-15186) in 3D tumor sphere models. Ravoxertinib hydrochloride can be used in research related to various cancers including breast cancer, melanoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and Merkel cell carcinoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

37

ARV-825

37 Cited Publications

Cat. No.: HY-16954

CAS No.: 1818885-28-7

Target:

PROTACs Epigenetic Reader Domain c-Myc Polo-like Kinase (PLK) CDK JAK STAT Pim Bcl-2 Family PAK Wnt β-catenin Caspase PARP Apoptosis Reactive Oxygen Species (ROS)

Research Areas:

Neurological Disease Cancer

ARV-825 is a BET protein PROTAC degrader that recruits cereblon, and it targets BRD2, BRD3, and BRD4 for degradation via the ubiquitin-proteasome pathway. ARV-825 downregulates c-MYC, PLK1, MYCN, CDK4/6, JAK2, pSTAT3/5, PIM1, and Bcl-xL, upregulates p21 and p27, and modulates H3K27Ac-mediated transcription, the G2/M checkpoint, the Wnt/β-catenin pathway, and amino acid transport pathways. ARV-825 induces G1 phase cell cycle arrest, caspase 3/PARP-mediated apoptosis, DNA damage, and reactive oxygen species (ROS) production, reduces mitochondrial respiration, and simultaneously inhibits cell proliferation, clonogenic growth, and cell migration. ARV-825 is used in research on gastric cancer, leukemia, neuroblastoma, and cholangiocarcinoma .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

30

ARV-771

30 Cited Publications

Cat. No.: HY-100972

CAS No.: 1949837-12-0

Purity: 98.87%

Target:

PROTACs Epigenetic Reader Domain Apoptosis Ferroptosis c-Myc Androgen Receptor

Research Areas:

Cancer

ARV-771 is a BET PROTAC degrader, with K_d values of 34, 4.7, 8.3, 7.6, 9.6 and 7.6 nM against BRD2 (1), BRD2 (2), BRD3 (1), BRD3 (2), BRD4 (1) and BRD4 (2) , respectively. ARV-771 inhibits the transcription of AR/AR-v7 and its downstream target genes. By degrading BRD4 protein, ARV-771 enhances the sensitivity of prostate cancer cells to ferroptosis, suppresses cancer cell viability, and induces apoptosis. ARV-771 downregulates the levels of BRD4, c-MYC and AR-V7 in tumor tissues and inhibits tumor tissue growth. ARV-771 can be used in prostate cancer-related research .

Compare

loading...

Please select quantity

August 31

Get Quote

View All Sizes

23

APTO-253

23 Cited Publications

Cat. No.: HY-16291

CAS No.: 916151-99-0

Synonyms: LOR-253; LT-253

Target:

c-Myc KLF Apoptosis

Research Areas:

Inflammation/Immunology Cancer

APTO-253 (LOR-253) is a small molecule that inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the Krüppel-like factor 4 (KLF4) tumor suppressor . APTO-253 has antiarthritic activity .

Compare

loading...